The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs. “In this scheme, CanaRx facilitates foreign physicians rewriting the employee’s U.S. prescription, and then supplies the employee with unapproved versions of FDA-approved drugs purportedly sourced from Canada, the United Kingdom or Australia that are represented to have undergone review from those countries’ drug regulatory systems,” FDA said. “This is particularly troublesome, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s ‘insurance’ plan and may not question their legitimacy.” The letter lists more than 150 websites affiliated with the company. FDA said health care providers and consumers should report any adverse events related to drugs provided by CanaRx to its MedWatch program.

Related News Articles

Headline
The Alliance for Addiction Payment Reform, whose members include the AHA, today showcased its value-based payment model for addiction and recovery support…
Headline
The AHA is engaging in early primary states, including Nevada and South Carolina, with ads about affordability and rural health care to ensure issues…
Headline
The House Ways and Means Committee today favorably reported out, as amended, the Consumer Protections Against Surprise Medical Bills Act (H.R. 5826), AHA-…
Headline
The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…
Headline
The Department of Health and Human Services today issued a proposed rule intended to clarify the rights and obligations of faith-based organizations…
Headline
Kansas Gov. Laura Kelly has reached agreement with Senate Republicans on a bipartisan proposal to expand Medicaid eligibility to low-income uninsured…